A. H. Robins Company, Incorporated

Societe D'etudes Scientifiques Et Industrielles De L'ile-de-france

Other

Laboratoires Delagrange (synthelabo)

Laboratoires Delagrange Div. Societe D'applications Pharmacodynamiques

Laboratoires Delagrange Societe D'application Pharmacodynamiques

Laboratoires Delagrange Societe D'applications Pharmacodnymiques

Societe D'etudes Scientifiques Et Industrielle De L'ile-d-france

Robert J Naylor

Brenda Costall

Jacques Acher

Jean-Claude Monier

Jean-Paul Schmitt

Renee Gardaix-Luthereau

Alain J Renaud

Brenda Naylor

Michel Langlois

Denis Besancon

Peter Jenner

Gardaix-Luthereau Renee

Charles D Marsden

Compounds of general formula I ##STR1## wherein: X represents oxygen or sulphur; each of R.sup.1 and R.sup.3 independently represents hydrogen or a C.sub.1 -C.sub.4 alkyl group;

Anxiolytic-R-n(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides

Anxiolytic and antipsychotic treatment is provided to patients by administering therapeutically effective amounts of N-[2-(diethylamino)-ethyl]-2-methoxy-4-[(1-H-4,5-dihydro-2-imidazolyl)-ami no]-5-chlorobenzamide, or a pharmaceutically acceptable salt thereof.

Method of providing anxiolytic and antipsychotic treatment

The present invention relates to the use of substituted benzamides of formula (1): ##STR1## in which: A is linear or branched C.sub.1 -C.sub.3 alkyl; allyl or diethylaminoethyl;

Method of increasing gastrointestinal motility with substituted

Anxiolytic and antipsychotic treatment is provided to patients by administering therapeutically effective amounts of N-[2-(diethylamino)-ethyl]-2-methoxy-4-[(1-H-4,5-dihydro-2-immidazolyl)-am ino]-5-chlorobenzamide, or a pharmaceutically acceptable salt thereof.

The invention relates to the use of benzamide derivatives of the formula: ##STR1## in which: A is a diethylaminoethyl group or a group of the formula II: ##STR2## where R is a C.sub.1 -C.sub.3 alkyl, allyl, cyclopropylmethyl or cyclohexenylmethyl group,

Method of treating disorders of cognitive function with substituted

The present invention relates to the application of substituted benzamides of formula (I): ##STR1## in which: A is diethylaminoethyl, 1-ethyl-2-pyrrolidinylmethyl or 1-allyl-2-pyrrolidinylmethyl;

Method of providing anxiolytic and antipsychotic treatment with

Compounds of general formula I ##STR1## wherein: X represents oxygen or sulphur;

Method of treating or preventing schizophrenia and/or psychosis using

Memory enhancing-R-N-(1-azabicyclo[2.2.2.]oct-3-yl)benzamides and

New substituted benzamides have the general formula: ##STR1## their optical isomers and their physiologically acceptable salts. The compounds are used as activators of the central nervous system.

Novel benzamides, intermediates and process for the preparation and

Compounds of general formula I: ##STR1## wherein: X represents oxygen or sulphur;

Anxiolytic-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides

2-Alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides having the formula ##STR1## wherein X is oxygen or sulphur; R.sub.1 is loweralkyl; and R.sub.2 is hydrogen, halo, 4,5-benzo, alkoxy or Am wherein Am is amino, methylamino or dimethylamino, and n is 1 or 2, and the pharmaceutically acceptable acid addition salts thereof have antischizophrenic activity.

2-Alkoxy-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamide and thiobenzamide

New substituted benzamides have the general formula: ##STR1## A=alkyl, alkenyl, diethylaminoethyl or ##STR2## R.sub.1, R.sub.2 =H, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl; R.sub.3, R.sub.4, R.sub.5, R.sub.6 =hydrogen or C.sub.1 -C.sub.6 alkyl;

The use of N-(1-allyl-2-pyrrolidinylmethyl) 2-methoxy 4-amino 5-methylsulphamoyl benzamide to treat Parkinson's disease.

Growing community of inventors

Ilkley, United Kingdom

Robert J Naylor